Abstract
Doxorubicin (DOX) is an effective chemotherapy. However, its usage has been associated with adverse effects. Salidroside (SAL) is an antioxidative drug, which confers protective effects against several diseases. Salidroside can attenuate cardiac dysfunction induced by DOX. Quaking (QKI) is identified as a protective factor that can inhibit cardiotoxicity medicated by DOX through the regulation of cardiac circular RNA expression. The present study investigated the role of QKI on the protective effect of SAL in the DOX-induced cardiotoxicity model. Results indicated that SAL attenuated DOX-induced adverse effects, including cardiac dysfunction, weight loss, and reactive oxygen species (ROS) production, and decreased the expression of BAX, caspase 3, and FoxO1. Also, it increased the Mn-SOD2 and QKI expression in vivo and in vitro. Furthermore, QKI knockdown suppressed anti-cardiotoxicity mediated by SAL. In conclusion, the results of the current study show that salidroside attenuates doxorubicin-induced cardiac dysfunction through activation of QKI/FoxO1 pathway.
References
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Mar 1, 1996·Nature Genetics·T A EbersoleK Artzt
Jul 31, 2003·Nucleic Acids Research·Zifan LuYue Feng
Jun 1, 2004·Pharmacological Reviews·Giorgio MinottiLuca Gianni
Jul 26, 2005·Nature Structural & Molecular Biology·André Galarneau, Stéphane Richard
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Apr 21, 2009·European Journal of Pharmacology·Tiejun WuWeiyong Liu
May 22, 2009·BMC Molecular Biology·André Galarneau, Stéphane Richard
Mar 29, 2011·Biochimica Et Biophysica Acta·Xinbo ZhangArun K Rishi
Dec 20, 2011·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Wangang GuoZifan Lu
Feb 20, 2013·Journal of Asian Natural Products Research·Mao-Chun XuHao Wang
May 1, 2013·Genes & Development·Marianna TeplovaDinshaw J Patel
Sep 28, 2013·Journal of Cardiovascular Pharmacology·Xu-Lei WangWei Jiang
Jul 30, 2014·Journal of Molecular and Cellular Cardiology·Wangang GuoHeng Ma
Jun 18, 2016·Cancer Biomarkers : Section a of Disease Markers·Cai LvZhi-Ming Bai
Nov 24, 2016·Oncotarget·Jingyuan LiPeili Bu
Jan 6, 2017·Scientific Reports·Hui LiuJinmin Zhao
Aug 2, 2017·Life Sciences·Xiaobin GuoPeili Bu
Sep 15, 2017·Journal of Cellular and Molecular Medicine·Lvyi ChenChunhua Ma
Oct 5, 2017·Scientific Reports·Monika Sharma, C R Anirudh
Nov 3, 2017·Frontiers in Pharmacology·Linjie JuLuan Shu
Nov 15, 2017·Circulation Research·Shashi Kumar GuptaThomas Thum
Dec 17, 2017·BMC Complementary and Alternative Medicine·Hai Li, Chen Chen
Jul 2, 2018·Journal of Pharmacological Sciences·Yan SunLei Shi
Aug 17, 2018·Biochemical Pharmacology·Xu ZhangChao Liu
Aug 25, 2018·Oxidative Medicine and Cellular Longevity·Tao ZhengSi Jin
Nov 20, 2018·Cancer Medicine·Young Ae KimHak Jin Kim
Apr 23, 2019·Cardiology in Review·Julia B Blanter, William H Frishman
Jul 10, 2019·Circulation·Sonia ChothaniOwen J L Rackham
Aug 26, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Chuanhong LuoDingkun Zhang